Deerfield Management, a hedge fund, led a $120m funding round in Aurion Biotech, a clinical stage biotech company, developing a transformational platform of advanced therapies to cure blindness, with participation from Petrichor Healthcare Capital Management, Flying L Partners, Falcon Vision, Visionary Ventures and Alcon. "Our financing speaks volumes about the potential of our cell therapy to transform the lives of millions of people suffering from corneal endothelial dystrophies. We are inspired and gratified by the strategic support, insights and depth of resources our investors bring to Aurion Biotech – all of which will help to accelerate our momentum," Greg Kunst, Aurion Biotech CEO.